The pharmacokinetics of intravenous ciprofloxacin and its metabolites were characterized in 42 subjects with various degrees of renal function (group 1, Ch (mL/min/l-73m
Introduction
Intravenous ciprofloxacin is approved for the treatment of many types of infections. Such infections are not uncommon in patients with renal failure. The currently approved dosage for iv ciprofloxacin is 200-400 mg given every 12 h. Several studies have been conducted in renally impaired subjects following the administration of oral ciprofloxacin doses of 250-750 mg (Boelaert et al., 1985; Danielson el al., 1985; Gasser et al., 1987; Singlas et al., 1987; Forrest et al., 1988; Kowalsky et al., 1993) or intravenous doses of 100-200 mg (Webb et al., 1986; Drusano et al., 1987) . All these studies show that the total body clearance and renal clearance of ciprofloxacin decreases with declining renal function suggesting that the doses of ciprofloxacin need to be reduced in patients with severe renal impairment. However, all of these studies used a single dose and none of them characterized the metabolites of ciprofloxacin. Four metabolites (Ml, M2, M3 and M4) of ciprofloxacin are formed in man (Zeiler et al., 1987) . Metabolite Ml (desethyleneciprofloxacin) and M2 (sulfociprofloxacin) have little activity, at least 30 times less than ciprofloxacin; M3 (oxociprofloxacin) has antibacterial activity about ten-fold less than ciprofloxacin. Metabolite M4 (formylciprofloxacin), a minor metabolite, is also about 10-fold less active than ciprofloxacin. Following iv administration of ciprofloxacin, approximately 60% of unchanged ciprofloxacin is excreted in urine and 15% in faeces. In urine and faeces approximately 2% of ciprofloxacin is excreted as Ml, 4% as M2 and 7% as M3. M4 was detected in the urine of only a few volunteers following an oral dose (Beermann et al., 1995) .
A dosage regimen as high as 400 mg every 8 h has been investigated for the treatment of severe respiratory tract infections (Fink et al., 1994) . Therefore it was important to investigate the pharmacokinetics of this high dose iv ciprofloxacin in subjects with various degrees of renal impairment. The objectives of this study were to characterize the pharmacokinetic profile of ciprofloxacin and its metabolites after single and multiple intravenous doses in subjects with normal renal function or with varying degrees of renal impairment in order to define a suitable dosage regimen for patients with renal failure.
Materials and methods

Subjects
Forty-two subjects from three centres participated in this study. Subjects were assigned to one of four renal function groups (Table I) based on a single 24 h creatinine clearance (C7 CT ) obtained within 7 days of dosing. The creatinine clearance was calculated from the 24 h urinary excretion of creatinine and the serum creatinine value. Subjects on theophylline, warfarin, glyburide or phenytoin were excluded from the study. Before dosing, a medical history was taken and a complete physical examination including vital signs, temperature, heart rate, respiration rate, and sitting blood pressure was performed on all prospective subjects. A 12-lead electrocardiogram, chest x-ray and a biochemical screening profile were also obtained. All subjects signed a written informed consent and the protocol was approved by the institutional review board at all three study sites.
Study design
This was an open-label, multiple-dose, parallel design, multi-centre study. On day 1 all subjects in group 1 (C/ CT > 90 mL/min/1-73 m 2 ), group 2 (C7 CT 61-90 mL/min/1-73 m 2 ) and group 3 (C/ CT 31-60 mL/min/1-73 m 2 ) received a single 400 mg dose and group 4 (C/c < 31 mL/min/1-73 nr) a 300 mg dose. All doses of intravenous ciprofloxacin in dextrose were infused over 1 h using a constant rate infusion pump. Blood and urine samples were collected over the next 24 h to assess the single dose pharmacokinetic profile. On day 2 subjects began multiple dose regimens consisting of intravenous ciprofloxacin 400 mg every 8 h for groups 1 and 2, 400 mg every 12 h for group 3 and 
Blood sample collection and handling
After the single dose on day 1 and the final dose on day 5, venous blood samples (5 mL each) were collected through an indwelling heparin lock device before drug administration and at the following times relative to the start of the 1 h infusion: 0-25, 0-5, 1 (end of 60 min infusion), 1-25, 1-5, 2, 3, 4, 6, 8, 10, 12, 16 , and 24 h after ciprofloxacin administration. Additionally, blood samples at 36 and 48 h were obtained after the last ciprofloxacin dose. In addition, pre-dose trough samples were collected before the first doses on days 3 and 4. Blood samples were collected in heparinized tubes and centrifuged within 1 h of collection. The plasma was separated and frozen at -20°C pending analysis.
Urine sample collection
For groups 1 and 2 urine was collected over the periods 0-8, 8-16 and 16-24 h following the single dose of ciprofloxacin on day 1 and following the final dose on day 5. For groups 3 and 4, urine was collected over the periods of 0-12 and 12-24 h following the single dose on day 1 and following the final dose on day 5. Additionally, for all groups, urine was collected over the periods of 24-36 and 36-48 h after the last dose on day 5. Total urine volume for each urine collection interval was determined and a 15 mL aliquot was frozen at -20°C for analysis of ciprofloxacin and its metabolites.
Microscopic examination for urine crystals
At one site (Millard Fillmore Hospital) the subjects were specifically asked to urinate 2 h after the ciprofloxacin dose. The volume and pH of urine were measured and two aliquots of 10 mL each were collected. One aliquot was used for microscopic examination for ciprofloxacin crystals and the other for the determination of ciprofloxacin concentration.
Safety evaluations
The iv site was examined routinely and any local reaction was recorded. Subjects were questioned in a systematic but non-specific way each day about possible adverse or unusual effects.
Assay
Concentrations of ciprofloxacin and its metabolites Ml (desethylene ciprofloxacin, BAY r 3964), M2 (sulfociprofloxacin, BAY s 9435), and M3 (oxociprofloxacin BAY q 3542) were analyzed in plasma and urine samples using a specific HPLC method with fluorescence detection. The procedure used for the analysis of ciprofloxacin and ciprofloxacin metabolites in plasma and urine is described in Krol, Beck & Benham (1995) . The quantitation range of the procedure is 005-7-5 mg/L for ciprofloxacin, 001-50 mg/L for metabolite Ml, 005-50 mg/L for metabolite M2, and 0-5-7-5 mg/L for metabolite M3. The coefficient of variation associated with inter-day precision and accuracy observed with all compounds at the lower and the upper limits of quantitation ranged from 2-5 to 8-3% at the lower limits and from 0-6 to 5% at the upper limits.
Pharmacokinetic and statistical analysis
The following parameters were calculated (using non compartmental methods) for ciprofloxacin on day 1 and day 5: ciprofloxacin plasma concentration at the end of infusion (C m ), C™, normalized to mg/kg dose (C^J, the area under the concentration time curve from time 0 to infinity (AUCo-«) on day 1 and from time 0 to T, where T is the dosing interval (AUCo-r) on day 5, the AUCs normalized to mg/kg dose (AUCoonn). The areas were calculated by the linear trapezoidal method in the ascending portion of the concentration time profile and the log trapezoidal method in the descending portion of the concentration time profile. For day 1, the terminal elimination rate constant, X, was estimated from the slope of the terminal exponential phase of the log plasma concentration vs time curve (using the linear regression method) using no less than three data points. The terminal elimination half-life (T, n ) was then calculated as 0-693/A. The steady state volume of distribution (V a ) and the total body clearance (C7) were calculated from day 1 data as ({Dose/AUCo_^}*{AUMCo-,c/ AUCo-oc -T/2}) and Dose/AUCo-oc, respectively, where T is the infusion time and AUMC is the area under the first moment of the concentration time curve. The AUMC is calculated by integrating the product of time and concentration from 0 to infinity (Gibaldi & Perrier, 1982) . The renal clearance was estimated by Ae^/AUC^) on day 1 and the Aeo-t /AUCo-, on day 5, where Ae refers to the amount of ciprofloxacin excreted over the designated time interval. The accumulation factors were determined as follows: AUCo_ t , day 5/AUCV,, day 1 and AUCo_ t , day 5/AUCV*, day 1. Effective 24 h AUC was determined by multiplying the AUCo_ t at steady state by the number of doses administered per day, e.g. AUQM X 3. Data are reported as geometric mean
The statistical analysis of the logarithms of the pharmacokinetic variables was performed using an analysis of variance including effects for centre and group. Comparisons of pairs were performed using 90% two-sided confidence intervals and two-sided tests of the hypothesis of equality of the groups.
Results
Demographics.
Patient demographics are presented in Table I . Forty-two subjects were enrolled in the study. All 42 subjects completed 1 day of dosing, and 39 completed 5 days of dosing. No subjects were excluded from the pharmacokinetic or safety analysis. Patients, especially with moderate and severe renal failure, were on multiple concomitant medications. Besides the usual 'renal' medications such as calcium supplements and 
Plasma concentration profiles
The mean plasma concentration versus time plots for ciprofloxacin and its Ml and M2 metabolites on day 5 are presented in Figures 1 to 3 . M3 metabolite concentrations were below the quantitation limit for most subjects at the majority of time points and, therefore, are not shown. In most subjects steady-state was achieved on day 5 or earlier for ciprofloxacin, the M1 metabolite or the M2 metabolite as indicated by trough levels on days 3, 4, and 5. Pharmacokinetic parameters for ciprofloxacin and its Ml and M2 metabolites are discussed below.
Ciprofloxacin pharmacokinetics
The dose and body weight normalized mean C m , values (C^,. norm ) on day 1 were similar for groups 1 and 2 but were significantly higher (P < 0004) by 28-32%, respectively, in groups 3 and 4 compared with group 1 (Table II) . The mean AUConn was 1 -4-to 3-4-fold higher (P ^ 0002) in groups 2, 3 and 4 compared with group 1. The 24 h AUC on day 5 was also 1-5-20-fold higher (P ^ 00007) in groups 2, 3 and 4 than in group 1. The ratio of day 5 AUCV./day 1 AUCV, was significantly higher (P *S 00001) in group 4 than in group 1.
The mean T\ a for groups 1 and 2 were similar (P = 0-28), whereas the mean T\ a for group 3 was 24% higher (P = 0044) and for group 4 was 79% higher {P < 00001) compared to group 1. The total body clearance and K u normalized to body weight was significantly lower in groups 2, 3 and 4 than in group 1. The Cl, and Cl m were significantly lower in groups 3 and 4 than in group 1. The decreased C/and Cl, in groups 2, 3 and 4 are consistent with the higher AUC and C™, values.
Ml metabolite {desethyleneciprofloxacin) pharmacokinetics
The dose and body weight normalized mean CM values (Cmu.,*,™) on day 1 were similar in groups 1, 2 and 3 but were significantly higher (P = 00009) by 76% in group 4 than in group 1 (Table III) . The mean AUC™™ was higher by 1-6-6-4-fold (P < 00072) in groups 2, 3 and 4 than in group 1. The effective 24 h AUC on day 5 was similar between groups 1 and 2 but the group 3 and 4 mean values were 1 -7-3-4 fold higher (P < 00008) than in group 1. The ratio of day 5 AUCo_ t /day 1 AUCo_ t was not significantly different between groups 2 and 3 compared with group 1 but was significantly higher (P < 00001) for group 4 than in group 1. The mean T ]a was 1-6-3-1-fold higher in groups 2, 3 and 4 than in group 1 (P s£ 00052). The day 1 Cl, was 44 to 92% lower in groups 2, 3 and 4 than in group 1 (P < 0009).
M2 metabolite (sulfociprofloxacin) pharmacokinetics
On day 1 the mean Cn^oom, was not significantly different between groups 1 and 2 (P = 0-28) but was significantly higher (P < 00001) by 2-2-5-fold for groups 3 and 4 compared with group 1 (Table IV) . The mean AUCno™ values were 3-8 and 14-7-fold higher (P ^ 00001) in groups 3 and 4, respectively compared with group 1. The effective AUCo-24 values for groups 3 and 4 were 2-4 and 5-4-fold higher (P < 00001) than in group 1. The ratio of AUCo_ T on day 5/AUCV t on day 1 was not significantly different between groups 2 and 3 compared with group 1 but was significantly higher (P < 00002) for group 4 than in group 1. The mean T m was 2-2-5-8-fold longer in groups 3 and 4 than in group 1 (P ^ 0001). The Cl, was 42-94% lower in groups 2, 3 and 4 compared with group 1 (P ^ 0-044).
Correlation between pharmacokinetic parameters and creatinine clearance
Exploratory regression analyses were performed between the pharmacokinetic parameters and C/ CT . Of particular interest were the plots of ciprofloxacin Cl and Cl, on day 1 versus baseline Cl a as shown in Figures 4 and 5. A positive correlation was observed between ciprofloxacin Cl and CL with a slope of 0-29 (r 2 = 0-78) and between ciprofloxacin Cl, and C/ CT with a slope of 019 (r 2 = 0-84). Similar correlations were also obtained between Ml and M2 metabolite Cl, and C/ CT .
Safety
All forty-two subjects were included in the safety analysis. The most common adverse reaction was infusion site irritation. In many of the subjects who had injection site reactions there was more than one event during the 5 day study. There were no deaths during this study. The intensity of all adverse events was mild or moderate. No clinically significant laboratory abnormalities related to treatment emerged during the study.
At one site (Millard Fillmore Hospital) the urine samples collected 2 h following the morning dose on days 2, 3 and 4 were examined for the presence of ciprofloxacin crystals. No ciprofloxacin crystals were found in these urine samples.
Discussion
All previous studies with ciprofloxacin in renal patients were single dose studies. In these studies ciprofloxacin was given as either a 100 mg (Webb et al., 1986) or 200 mg single iv dose (Drusano et al., 1987) or as 250, 500, and 750 mg oral doses (Boelaert et al., 1985; Danielson et al., 1985; Gasser et al., 1987; Singlas et al., 1987; Forrest et al., 1988; Kowalsky et al., 1993) . These studies showed that the total body clearance (CY) was degreased by 2-to 4-fold and Cl, was decreased by four-to six-fold in subjects with creatinine clearance values ranging from 5 to 50 mL/min. As a consequence of these pharmacokinetic alterations it has been recommended that a reduction in ciprofloxacin dose occur in subjects with severe renal impairment. The results of the current study are consistent with the previous findings, and provide a basis for dosage recommendations at the higher doses of ciprofloxacin currently being investigated. In the present multiple dose study the plasma concentrations of ciprofloxacin and its metabolites (Ml and M2) were characterized in subjects with varying degrees of renal function. The data from our studies demonstrate that plasma concentrations of ciprofloxacin and its Ml and M2 metabolites increase as C/ CT decreases. These results indicate that the excretion of the Ml and M2 metabolites is partially renal dependent. The pharmacokinetic parameters of ciprofloxacin were affected to some degree in group 2 and 3 subjects but the more significant pharmacokinetic alterations did not develop until C/ CT values fell below 30 mL/min/1-73 m 2 . In this study group 3 subjects received doses of 400 mg every 12 h which provided ciprofloxacin plasma concentrations similar to those seen in group 2 subjects given 400 mg of ciprofloxacin every 8 h. Subjects in group 4 who were dosed with 300 mg 12 hourly achieved greater AUC and C^ values for ciprofloxacin and metabolite than groups 1 to 3. Therefore, in this group, a still lower dosage should be considered. In the clinical study described in Fink et al. (1994) , a dosage regimen of 400 mg iv tid was used for patients with C/ CT > 70 mL/min, that would correspond to group 1 and some subjects from group 2 in the study described here. Therefore, in the study described here, the plasma levels were titrated to group 2 instead of group 1. In the study described here, no females were enrolled in the group with C/ CT > 90 mL/min, because in general women have a lower C/ CT than males especially in that age group (in trying to match the ages across the four groups with an average age of around 50 years, it was not possible to find females or males who were that old and had C/ CT > 90 mL/min). Due to these reasons it was felt that the plasma concentrations in group 2 were more appropriate for comparison. In order to explore the likely effects of alternative regimens for group 4, the data from group 4 were modeled using PCNONLIN. The mean concentrations for this group were fitted using PCNONLIN. A two compartment model with constant iv input and first order output provided the best fit. Parameter estimates from this fit were used to simulate concentration time profiles for other dosing regimens. The resulting concentration profiles were compared to the concentrations observed in groups 1, 2 and 3. For ciprofloxacin, the predicted AUC and Cm., values for subjects with C/ CT ^ 30 mL/min/1-73 m 2 on regimens of 200 mg twice a day and 400 mg daily are presented in Table V . The results indicate that the predicted C miU for the 200 mg 12 hourly regimen is slightly lower than the actual C™* in groups 1, 2, and 3. The predicted C™, for the 400 mg daily regimen is similar to that observed in groups 2 and 3 but higher than that in group 1. The effective steady-state AUCs over a 24 h period for both the 200 mg 12 hourly and 400 mg daily regimens were similar to those seen for groups 2 and 3.
For the M1 and M2 metabolites, the steady-state Cm, and effective 24 h steady-state AUC values predicted for the 400 mg every 24 h regimen in group 4 were higher than the corresponding values observed for groups 1, 2 or 3 at the experimental doses (Table V) . Since Ml and M2 have very little antibacterial activity as compared to ciprofloxacin the antibacterial activity that could potentially be provided by the AUCs of Ml and M2 were not considered in dosage recommendation of ciprofloxacin. , a dosage regimen of 400 mg daily will provide plasma concentrations similar to those observed in subjects with C/ CT between 61-90 mL/min/ 1-73 m 2 given 400 mg every 8 h.
